Patient Care Online reported on new data presented by HSS at the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting that challenges a long-standing clinical assumption: OI is best suited for transfemoral (above-the-knee) amputees. Taylor J. Reif, MD, limb lengthening and orthopedic oncology surgeon at HSS spoke with the outlet about the findings.

“There are no studies in the scientific literature focusing on differences in safety and outcomes of patients who underwent transfemoral osseointegration as compared to those who had transtibial osseointegration,” said Dr. Reif.

Investigators at HSS studied 147 limb segments, 83 femoral and 64 tibial, and found both cohorts achieved significant postoperative improvements in mobility and quality of life. Transtibial patients demonstrated a greater magnitude of improvement across patient-reported outcome measures, including LD-SRS and PROMIS survey domains, despite entering surgery with higher baseline mobility than femoral patients.

Read the full article at patientcareonline.com.